1698 – Chronic Pain MedChecks Trial

Page last updated: 01 March 2022

Application Detail

Description of Medical Service

The Chronic Pain MedsCheck Trial assessed the effectiveness of a pharmacist-led, patient-centred service to support patients that are taking medication to manage chronic pain, and that are identified as experiencing self-management or pain medication dependency issues.

The trial compared two service models of review, assessment and support; one model had two clinical consultations and the second model had three clinical consultations.

Description of Medical Condition

The trial recruited participants who:

  • attended a community pharmacy
  • were over the age of 18
  • held a valid Medicare card and/or Department of Veterans’ Affairs card
  • were living at home in a community setting
  • had suffered from chronic pain for three months or longer
  • had not had a Home Medicines Review, MedsCheck, Diabetes MedsCheck or Chronic Pain MedsCheck within the previous 12 months
  • had been taking medication (prescription or over the counter) for their pain
  • were identified by a community pharmacist as either experiencing self-management or dependency issues, and
  • were not a current client of a recognised Pain Management Service.

Reason for application

The 6CPA provided funding to support a Pharmacy Trial Program (PTP), which seeks to improve clinical outcomes for patients and/or utilise the full scope of a pharmacist’s role in delivering primary health care services.

The outcomes of all PTP Trials will undergo an independent Health Technology Assessment (HTA) to determine the effectiveness and cost-effectiveness of the trial intervention and inform decisions about any broader rollout. A decision to fund any future programs would be a matter for Government.

Information on the PTP is available on the Department of Health’s website.

Medical Service Type

Therapeutic technology

Previous Application Number

Not applicable

Associated Documentation

CPMC Consultation Summary

CPMC Consultation Summary (PDF 1691 KB)
CPMC Consultation Summary (Word 1063 KB)

Consultation Survey

Consultation Survey (PDF 669 KB)
Consultation Survey (Word 75 KB)

MSAC welcomes public consultation input as per the CPMC Consultation Summary above. Please send feedback on this application to CommentsMSAC@health.gov.au (and cc: pharmacy.trial.program@health.gov.au) including the MSAC application number 1698 in the subject heading of your email.

PASC Consultation
Not applicable

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 10 June 2022 for it to be considered by MSAC at its July 2022 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

Not applicable

Assessment Report


Public Summary Document


Meetings for this Application


Bypassing PASC


9–10 June 2022


28–29 July 2022